INTERVENTIONALRECRUITINGNCT06692933

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.

Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-06-04

What this record can show

Protocol only - no registry results posted

This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.

Registry facts

Study at a glance

Phase: EARLY PHASE1
Enrollment: 24 (ESTIMATED)
Start date: 2024-06-20
Sponsor: Washington State University
Design: NON RANDOMIZED · CROSSOVER · BASIC SCIENCE
Locations: 1
Results record: Not present in registry snapshot

The popularity of cannabis products has grown exponentially over the past decade as several states continue to decriminalize or legalize recreational and/or medicinal use. Cannabis contains \>500 phytoconstituents, including \>100 cannabinoids. The most well-studied cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD). Although both are psychoactive, THC produces the characteristic "high," while CBD does not. CBD is available as a prescription drug (Epidiolex®) to treat seizure disorders. Hemp, a popular CBD-containing botanical product, is defined as containing \<0.3% THC. Hemp was federally legalized in the United States in 2018 following passage of the Farm Bill. Since passage of that bill, hemp and other CBD-containing products have become widely available over the counter. As such, hemp/CBD products have become top-selling botanicals, with sales projected to reach nearly $4.5 billion by 2024. Common uses include self-treatment for pain, anxiety, and sleep disorders. Despite increasing use of cannabis products, the pharmacokinetic interaction potential with pharmaceutical medications remains understudied. Previous pharmacokinetic studies have yielded convincing evidence that CBD significantly inhibits the activity of the drug metabolizing enzyme cytochrome P450 (CYP) 2C19. Despite the valuable information generated by these and numerous other studies, several unanswered questions about CBD-containing products remain: 1. Do real-world doses and dosing regimens of CBD (\< 300 mg) have similar CYP interaction potential as that of higher doses investigated in previous pharmacokinetic studies? 2. What are the effects of CBD on high-impact CYP2C19 substrates, such as the anti-platelet drug clopidogrel (Plavix®)? 3. Does chronic administration of a real-world dose of CBD have similar interaction potential as a very high single dose of CBD? The primary objective of the proposed study is to evaluate the effects of a well-characterized, widely used hemp product on the pharmacokinetics of the commonly prescribed CYP2C19 substrate clopidogrel (Plavix®) in healthy adult participants who are confirmed to be CYP2C19 normal, rapid, or ultra-rapid metabolizers. Results could be used to inform a future study design involving elderly people, which is a population of interest. Results could also be used to guide healthcare providers in helping their patients make informed decisions about the safe use of hemp

Linked local records

Related local records

Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.

Conditions

No published condition report matched.

Cannabinoids and active compounds

cannabidiol

Medicines

No exact medicine-name link was found.

Interventions

What was registered

DRUG

Cannabidiol in the form of hemp

Cannabidiol (30 mg) in the form of an orally administered hemp oil softgel

CBD

DRUG

Clopidogrel

75 mg oral clopidogrel

Plavix

Eligibility

Population and criteria

Sex: ALL
Minimum age: 21 Years
Maximum age: 64 Years
Healthy volunteers: Accepted

Inclusion criteria

21-64 years old and healthy;
Confirmed by genetic test to be a CYP2C19 normal, rapid, or ultra-rapid metabolizer;
Not taking any medications (prescription and non-prescription, including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Have taken hemp or cannabis (in any form) before and tolerated it well;
Willing to abstain from consuming dietary supplements/botanical products and citrus juices for the duration of the study;
Willing to abstain from cannabis/marijuana, hemp, THC- and/or CBD-containing products for several weeks;
Willing to abstain from consuming caffeinated beverages or other caffeine-containing products the evening before and morning of any inpatient day;
Willing to abstain from consuming alcoholic beverages for one day prior to any inpatient day;
Willing to use a secondary method of birth control that does not include the introduction or discontinuance of hormonal-based birth control (such as abstinence, copper IUD, or condoms), continuing for 1 week after completing the study;
Have the ability to and are willing to comply with the requirements of the study;
Geographically located within a 40-mile radius of Spokane and have the time to participate and;
Can read and speak English

Exclusion criteria

Under the age of 21 or over the age of 64;
Any major illness;
Pregnant or nursing;
History of allergy or intolerance to cannabis or clopidogrel;
Taking concomitant medications, both prescription and non-prescription (including clopidogrel) or dietary supplements/botanical products known to alter the pharmacokinetics of cannabis and/or clopidogrel;
Never taken cannabis (in any form) before;
Presence of a condition or abnormality that, in the opinion of the Investigator, would compromise participant safety or the quality of the data;
Currently using or have recently used drugs or other illicit substances for recreational purposes;
Have used cannabis/marijuana, hemp, THC- and/or CBD-containing products within the last 4 weeks;

primary outcomes

primary measures

AUC ratio of clopidogrel active metabolite

Time frame: 0-24 hours

Ratio of the area under the plasma concentration vs. time curve of the active metabolite of clopidogrel in the presence to absence of hemp

secondary outcomes

secondary measures

Cannabidiol AUC

Time frame: 0-72 hours

Area under the plasma concentration vs. time curve of cannabidiol

AUC of cannabidiol metabolites

Time frame: 0-72 hours

Area under the plasma concentration vs. time curve of cannabidiol metabolites

Publications

Locally readable linked articles

No exact PMID-linked public article is currently readable locally.

Snapshot provenance

Snapshot: 61bddba3-531f-4e68-9a95-f39f3511397c
Retrieved: 24/09/2026, 14:13:46
SHA-256: e947c2e98cd67a4258f3dfeec0a5c94444f1767a609d90245d3cc7b909a48b58